Atiq, O.T., Kemeny, N., Niedzwiecki, D. and Boter, J. (1992) Treatment of Unresectable Primary Liver Cancer with Intrahepatic Fluorodeoxyuridine and Mitomycin C through an Implantable Pump. Cancer, 69, 920-924.
http://dx.doi.org/10.1002/1097-0142(19920215)69:4<920::AID-CNCR2820690414>3.0.CO;2-Y

has been cited by the following article:

• TITLE: Efficacy of 5-Fluorouracil and High-Concentration Cisplatin Suspended in Lipiodol by Short-Term Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis

  AUTHORS: Yutaka Yata, Masashi Namikawa, Tatsuya Ohyama, Takashi Ohsaki, Daisuke Kanda, Takeshi Hatanaka, Kei Shibuya, Jun Kubota, Hitoshi Takagi, Terumi Takahara, Teruo Yoshinaga

  KEYWORDS: Advanced Hepatocellular Carcinoma (HCC), Portal Vein Tumor Thrombosis (PVTT), Hepatic Arterial Infusion Chemotherapy (HAIC), 5-FU, a Fine-Powder Formulation of Cisplatin, Quality of Life (QOL), Cost-Effective Treatment

  JOURNAL NAME: Journal of Cancer Therapy, Vol.6 No.13, December 3, 2015

  ABSTRACT: Background: Since advanced hepatocellular carcinoma (HCC) is potentially fatal, and patients’ quality of life (QOL) often deteriorates during their treatment, improving the prognosis and QOL of patients given chemotherapy is very important. In addition, cost-effective treatments are highly desirable when chemotherapy must be given repeatedly. The aim of this study was to evaluate the efficacy and usefulness of 5-fluorouracil (5-FU) and high-concentration cisplatin by short-term hepatic arterial infusion chemotherapy (3-day FPL) in advanced HCC patients. Methods: Thirty patients with unresectable advanced HCC were enrolled. The patients underwent hepatic arterial infusion chemotherapy via the implanted port system with 5-FU on days 1 - 3 and a fine-powder formulation of cisplatin in suspended pre-warmed lipiodol on day 2 every 4 to 10 weeks. Tumor response was assessed one month later with CT. Results: All patients had evidence of portal vein invasion (Vp2-4). Four patients achieved a complete response (CR), 8 patients achieved a partial response (PR), and 7 patients had stable disease (SD). The median progression-free survival (PFS) and overall survival (OS) were 198 days and 452 days, respectively. The OS was significantly longer in the successful disease control group (CR, PR, and SD) than in the progressive disease group (P